TL;DR
In vivo CAR-T is poised to broaden the reach of cellular immunotherapy, provided that its development is guided by rigorous pharmacology, chemistry, manufacturing and controls, and long-term molecular safety surveillance.
This review highlights how CAR-based strategies can be adapted across diverse disease settings by redirecting engineered immune responses toward disease-sustaining cellular compartments and position programmable cellular immunotherapy as a broadly adaptable platform for eliminating persistent pathological cells, remode...
Although still in its infancy, in vivo genetic engineering shows promise for CAR T cell therapy in a wide range of cancer patients and has the potential to reprogram patients’ immunity in autoimmunity, chronic infections, and regenerative medicine.
Preclinical studies are described demonstrating that UB-VV400 generates anti-CD22 CAR T cells that kill CD22-expressing B cells and tumor cells in vitro and in vivo, and that engagement of RACR results in the selective expansion and enrichment of CAR T cells in vivo leading to complete tumor clearance and B cell deplet...
The characteristics and clinical trials of CAR-T and TCR-T for cancer and autoimmune diseases are summarized and differences, challenges and prospect of these ACTs are described for reference to novel strategy of ACT.
Current challenges in solid tumour treatment are examined through evidence from clinical trials, highlighting key obstacles such as antigen heterogeneity, the immunosuppressive tumour microenvironment, poor cellular trafficking, and treatment-related failures that have informed the development of next-generation CAR co...
This review highlights key engineering strategies enabling in vivo CAR T-cell generation, summarizes emerging clinical research and development, and discusses future opportunities for expanding in vivo CAR T-cell therapies as scalable immunotherapy platforms.
We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.
